---
layout: report
type: weekly
topic_slug: chronic_migraine
topic_display: "Chronic Migraine"
week_start: 2025-08-25
week_end: 2025-08-31
permalink: /topics/chronic_migraine/weekly/2025-08-25/
source_run_ids:
  - chronic_migraine_20250826_091029
  - chronic_migraine_20250827_091408
  - chronic_migraine_20250828_091013
  - chronic_migraine_20250829_141515
  - chronic_migraine_20250830_090920
topics_covered:
  - Chronic Migraine
---

# Weekly Research Summary: Chronic Migraine

**Disclaimer:** This summary is generated by an AI assistant and is for informational purposes only. It is not a substitute for professional medical advice. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment.

---

### **TL;DR: Key Takeaways This Week**

-   New CGRP-targeted therapies, including monoclonal antibodies (mAbs), oral gepants, and nasal sprays, offer significant advancements for both preventing and acutely treating chronic migraine, often with fewer systemic side effects than older medications.
-   Consistent and detailed symptom tracking is a critical tool for all migraine patients, enabling identification of triggers, early intervention, and objective assessment of treatment effectiveness for personalized care.
-   Caretakers play a vital role in acute migraine management, from preparing personalized comfort kits to understanding acute medication protocols and recognizing critical red flags that necessitate emergency medical attention.

---

## Detailed Synthesis

### Advancements in Migraine Management: The CGRP-Targeted Revolution

This week highlighted the transformative impact of Calcitonin Gene-Related Peptide (CGRP)-targeted therapies in managing chronic migraine. These precision medications, including monoclonal antibodies (mAbs), oral gepants, and nasal sprays, specifically block CGRP or its receptor, a key pathway in migraine pain transmission.

For **prevention**, CGRP monoclonal antibodies like Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality), and Eptinezumab (Vyepti) offer a monthly or quarterly regimen, significantly reducing migraine days for many patients. Oral gepants, such as Atogepant (Qulipta), also provide a daily preventive option. These are typically considered for individuals with frequent migraines who haven't responded to or tolerated traditional preventives. While generally well-tolerated, side effects can include injection site reactions, constipation, fatigue, or nausea. Full therapeutic effects often take 2-3 months.

In **acute treatment**, oral gepants like Ubrogepant (Ubrelvy) and Rimegepant (Nurtec ODT) offer on-demand relief, with Rimegepant uniquely approved for both acute and every-other-day preventive use. The nasal spray Zavegepant (Zavzpret) provides rapid acute relief, particularly beneficial for quick-onset migraines or when nausea prevents oral intake. These newer options are generally safer for patients with cardiovascular concerns, unlike some older acute medications, and do not carry the same risk of Medication Overuse Headache (MOH). Common acute gepant/nasal spray side effects include nausea, fatigue, nasal discomfort, or altered taste.

It is crucial for patients to discuss all existing health conditions and medications with their neurologist to ensure these targeted therapies are appropriate, especially given potential interactions or contraindications related to liver/kidney impairment or pregnancy/breastfeeding.

### Optimizing Acute Attack Management and Preventing Medication Overuse

Effective management of acute migraine attacks involves a strategic approach, balancing rapid relief with the prevention of Medication Overuse Headache (MOH). Traditional acute treatments include NSAIDs for mild attacks and triptans (e.g., sumatriptan, zolmitriptan) for moderate to severe migraines. Triptans, available as oral tablets, nasal sprays, and injectables, work by targeting serotonin receptors. However, their use must be strictly limited, typically to no more than 9 days per month, to avoid MOH, where frequent use paradoxically worsens headaches. Triptans are also contraindicated for individuals with uncontrolled hypertension, heart disease, or a history of stroke.

Newer options, such as ditans (e.g., lasmiditan), specifically target serotonin 1F receptors without causing vasoconstriction, making them a safer alternative for some cardiovascular patients. As mentioned, oral gepants for acute use also provide a valuable alternative, as they do not carry the same MOH risk as triptans.

For caretakers, rapid administration of prescribed acute medication at the first sign of a migraine is key. Observing the patient for effectiveness and side effects within 30-60 minutes, and strictly adhering to prescribed dosages, is vital. Any medication efficacy or side effect concerns should be promptly discussed with the treating physician.

### Empowering Self-Management: Tracking, Personalization, and Non-Pharmacological Support

A cornerstone of effective chronic migraine management for both patients and caretakers is proactive self-management. **Symptom tracking** is identified as an essential first step for the newly diagnosed and a continuous tool for all. By consistently logging details such as headache severity, associated symptoms (nausea, aura), potential triggers (foods, stress, sleep patterns, weather), medication use (dose, time, effectiveness, side effects), and lifestyle factors, patients can uncover unique migraine patterns. This data empowers early intervention, helps identify and mitigate triggers, objectively assesses treatment effectiveness, and provides invaluable information for neurologists to tailor personalized care plans.

Beyond medication, caretakers can significantly enhance comfort during acute attacks by assembling a **personalized migraine comfort kit**. This kit is a *supplement* to prescribed acute medications, not a replacement. Essential components can include weighted/hot/cold eye masks, noise-canceling headphones, cautiously introduced aromatherapy (e.g., personal inhaler sticks), topical gels (magnesium, menthol), electrolyte-rich fluids, bland snacks, and soft clothing. Practical advice for caretakers includes consulting healthcare providers before introducing new items, refining the kit through patient feedback and tracking, and creating portable versions for various locations to ensure comfort is always accessible.

<h3>Recognizing and Responding to Migraine Emergencies</h3>

While managing chronic migraine, it is critical for both patients and caretakers to distinguish a severe migraine attack from a medical emergency. Prompt action can be life-saving.

**Immediate 911 calls are warranted for:**
-   A sudden, severe "thunderclap" headache that reaches peak intensity within seconds to minutes, often described as the "worst headache of my life," which could indicate a subarachnoid hemorrhage.
-   Sudden, significant neurological changes such as weakness, numbness, difficulty speaking, vision changes (beyond typical aura), confusion, or loss of consciousness, which may signal a stroke or seizure.

**Urgent evaluation at an emergency room is necessary for:**
-   Headache accompanied by fever, a stiff neck, or a rash, which could suggest meningitis or encephalitis.
-   A new headache following head trauma, requiring evaluation for concussion or intracranial bleeding.
-   A new headache in an individual over 50, to rule out conditions like giant cell arteritis or tumors.
-   Concerning changes in the usual migraine pattern, including sudden, drastic shifts in frequency, intensity, or character.

While waiting for emergency help, keep the patient calm and comfortable, ideally in a dark, quiet room if tolerated. It's crucial **not to administer additional medication unless instructed by emergency personnel.** Trusting instincts and seeking prompt evaluation are paramount in these critical situations.

**week_topics:**
-   Chronic Migraine Treatment
-   CGRP Therapies
-   Migraine Prevention
-   Acute Migraine Management
-   Symptom Tracking Migraine
-   Migraine Comfort Kit
-   Migraine Emergency Care
